Reported about 3 hours ago
Lundbeck A/S, a Danish pharmaceutical company, has agreed to purchase Longboard Pharmaceuticals for $2.6 billion to acquire its promising epilepsy drug candidate. The deal will enhance Lundbeck's portfolio focused on neurological disorders and is expected to close by the end of the year. The new drug, aimed at treating severe epilepsies known as Developmental and Epileptic Encephalopathies, could potentially generate peak sales of up to $2 billion.
Source: YAHOO